Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multicenter, Open-Label Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Next Previous
X
Search
Trial Profile

A Phase 1, Multicenter, Open-Label Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CC-95266 (Primary) ; Bendamustine; Cyclophosphamide; Fludarabine
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man
  • Sponsors Juno Therapeutics

    • Most Recent Events

    • 24 Jan 2024 Status changed from recruiting to active, no longer recruiting.
    • 12 Dec 2023 Results (As of May 24, 2023, n=70 ) of updated safety and efficacy, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 11 Dec 2023 According to a Bristol-Myers Squibb media release, results from this trial were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top